Largest positions
| Issuer | Class | Value | Share |
|---|---|---|---|
| Praxis Precision Medicines ICOM NEW | COM NEW | $27.7M | 19.3% |
| Whitehawk Therapeutics Inc.COM | COM | $21.5M | 15.0% |
| Tango Therapeutics Inc.COM | COM | $12.2M | 8.5% |
| Sutro Biopharma Inc.COM | COM | $8.97M | 6.3% |
| Arrivent Biopharma Inc.COM | COM | $7.6M | 5.3% |
| 4d Molecular Therapeutics Inc.COM | COM | $6.75M | 4.7% |
| Bright Minds Biosciences Inc.COM NEW | COM NEW | $6.51M | 4.5% |
| Ocular Therapeutix Inc.COM | COM | $5.23M | 3.6% |
| Erasca Inc.COM | COM | $4.86M | 3.4% |
| Surrozen Inc.COM NEW | COM NEW | $4.5M | 3.1% |
| Argen SE - ADRSPONSORED ADR | SPONSORED ADR | $4.37M | 3.0% |
| Moonlake ImmunotherapeuticsCLASS ORD A | CLASS ORD A | $4.2M | 2.9% |
| Design Therapeutics Inc.COM | COM | $4.09M | 2.8% |
| Minerva NeurosciencesCOM NEW | COM NEW | $3.94M | 2.7% |
| Taysha Gene Therapies Inc.COM SHS | COM SHS | $3.83M | 2.7% |
| Avalyn Pharma Inc.COM SHS | COM SHS | $3.79M | 2.6% |
| Avalo Therapeutics Inc.COM NEW | COM NEW | $3.44M | 2.4% |
| Amylyx Pharmaceuticals Inc.COM | COM | $3.02M | 2.1% |
| Artiva Biotherapeutics Inc.COM | COM | $2.53M | 1.8% |
| Compass Therapeutics Inc.COM | COM | $1.3M | 0.9% |
| United Therapeutics Corp.COM | COM | $1.21M | 0.8% |
| Contineum Therapeutics Inc.-aCL A | CL A | $1.03M | 0.7% |
| LB Pharmaceuticals Inc.COM SHS | COM SHS | $939K | 0.7% |
- Class
- COM NEW
- Share
- 19.3%
- Class
- COM
- Share
- 15.0%
- Class
- COM
- Share
- 8.5%
- Class
- COM
- Share
- 6.3%
- Class
- COM
- Share
- 5.3%
- Class
- COM
- Share
- 4.7%
- Class
- COM NEW
- Share
- 4.5%
- Class
- COM
- Share
- 3.6%
- Class
- COM
- Share
- 3.4%
- Class
- COM NEW
- Share
- 3.1%
- Class
- SPONSORED ADR
- Share
- 3.0%
- Class
- CLASS ORD A
- Share
- 2.9%
- Class
- COM
- Share
- 2.8%
- Class
- COM NEW
- Share
- 2.7%
- Class
- COM SHS
- Share
- 2.7%
- Class
- COM SHS
- Share
- 2.6%
- Class
- COM NEW
- Share
- 2.4%
- Class
- COM
- Share
- 2.1%
- Class
- COM
- Share
- 1.8%
- Class
- COM
- Share
- 0.9%
- Class
- COM
- Share
- 0.8%
- Class
- CL A
- Share
- 0.7%
- Class
- COM SHS
- Share
- 0.7%
The share class is shown on a wider screen.
The 23 largest of 23 positions by value, with holdings of the same security combined. Share counts and quarter-on-quarter changes for each position are on EDGAR. View the full information table on EDGAR
This filing
- Form
- 13F-HR
- CIK
- 1582844
- File number
- 028-16527
- Options
- 0 call, 0 put
- In the 25 largest
- 100.0%
- Prior quarter
- $142M at 31 March 2026
- Positions opened
- 5
- Positions closed
- 9
Common questions
What are Acuta Capital Partners’ 13F holdings worth?
$143 million across 23 positions for the quarter ended 30 June 2026.
What is Acuta Capital Partners’ largest 13F holding?
PRAXIS PRECISION MEDICINES I (COM NEW) was the largest position at $27.7 million, or 19.3% of reported 13F value, as of 30 June 2026.
How concentrated is Acuta Capital Partners’ 13F portfolio?
The ten largest positions accounted for 73.7% of reported value and the twenty-five largest for 100.0%, across 23 positions as of 30 June 2026.
Does Form 13F show everything Acuta Capital Partners manages?
No. Form 13F covers only long positions in exchange-traded securities over which the manager has investment discretion, valued at quarter end. It excludes cash, most bonds, private funds, and any assets the firm does not have discretion over, so it is neither the firm's total assets nor any individual client's portfolio.
How often does Acuta Capital Partners file its 13F?
Every quarter. Managers file within 45 days of each quarter's end, so the figures are a snapshot that changes between filings. This page shows the quarter ended 30 June 2026.
Answered from this filing and the prior quarter's.